COLORADO
Study: Phase II, Open label trial of MBC-11 for the treatment of canine myeloma.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org/phase-II-mbc-11
Eligibility: Dogs with a confirmed diagnosis of multiple myeloma are eligible for this study. Dogs must undergo some
diagnostic testing prior to starting the study to ensure that they are eligible. They must have good function of liver and
kidneys, have acceptable blood cell counts, and are free of severe underlying disease. A three-week washout from
chemotherapy and a 72-hour washout period from corticosteroids is required prior to enrollment.
Summary: Multiple myeloma is an uncommon but uniformly fatal canine disease. While the majority of dogs will respond to
chemotherapy utilizing standard cytotoxic agents as described in humans (e.g. melphalan, vincristine, doxorubicin),
greater than 95% of dogs will relapse with chemotherapy-refractory disease. The median survival time is approximately
1.5 years from diagnosis. Recent evidence suggests that the etidronate-AraC conjugate MBC-11 may have substantial
antitumor and antiresorptive effects in mouse models of myeloma. However, conventional mouse subcutaneous
xenografts may not accurately recapitulate the effect of MBC-11 on inhibition of myeloma progression. For this reason,
clinical evaluation of MBC-11 will be performed in dogs with spontaneous myeloma.
Requirements: Owners are responsible for the cost of diagnosing the dog's myeloma prior to entering the study. The
owner is expected to make and keep all appointments according to the study protocol, and must be committed to
completing the entire study protocol and follow-up examinations.
Financial Incentives: Clients participating in this study will be given special financial considerations. Specifically, all costs
related to the study are covered, and the owner will receive a $1000 credit to their account at the completion of the study.
Study: Phase II, Open label trial of MBC-11 for the treatment of canine myeloma.
Location: Colorado State University Animal Cancer Center, Fort Collins, CO
Phone: 970-297-4195
www.csuanimalcancercenter.org/phase-II-mbc-11
Eligibility: Dogs with a confirmed diagnosis of multiple myeloma are eligible for this study. Dogs must undergo some
diagnostic testing prior to starting the study to ensure that they are eligible. They must have good function of liver and
kidneys, have acceptable blood cell counts, and are free of severe underlying disease. A three-week washout from
chemotherapy and a 72-hour washout period from corticosteroids is required prior to enrollment.
Summary: Multiple myeloma is an uncommon but uniformly fatal canine disease. While the majority of dogs will respond to
chemotherapy utilizing standard cytotoxic agents as described in humans (e.g. melphalan, vincristine, doxorubicin),
greater than 95% of dogs will relapse with chemotherapy-refractory disease. The median survival time is approximately
1.5 years from diagnosis. Recent evidence suggests that the etidronate-AraC conjugate MBC-11 may have substantial
antitumor and antiresorptive effects in mouse models of myeloma. However, conventional mouse subcutaneous
xenografts may not accurately recapitulate the effect of MBC-11 on inhibition of myeloma progression. For this reason,
clinical evaluation of MBC-11 will be performed in dogs with spontaneous myeloma.
Requirements: Owners are responsible for the cost of diagnosing the dog's myeloma prior to entering the study. The
owner is expected to make and keep all appointments according to the study protocol, and must be committed to
completing the entire study protocol and follow-up examinations.
Financial Incentives: Clients participating in this study will be given special financial considerations. Specifically, all costs
related to the study are covered, and the owner will receive a $1000 credit to their account at the completion of the study.
| PET CANCER CENTER Comprehensive guide to cancer diagnosis and treatment in cats and dogs |
© 2007 Pet Cancer Center. ALL RIGHTS RESERVED.
Last updated 1/22/12
Please take our short survey to help us understand pet owners' perception of clinical trials.
| Clinical trials for dogs with multiple myeloma |
Find clinical trials for specific tumor types in dogs:
| Open clinical trials for dogs |